



LBT INNOVATIONS
ACN 107 670 673

The Manager
Company Announcements Office
ASX Limited

LBT RECEIVES NOTICE OF ALLOWANCE FOR THIRD PATENT RELATED TO CORE APAS® TECHNOLOGY IN UNITED STATES

Adelaide, 7 April 2016: Australian medical technology company LBT Innovations Limited (ASX: LBT) has received a Notice of Allowance from the US Patent & Trademark Office for a United States patent protecting the image capture technology of its Automated Plate Assessment System (APAS®).

The patent application is the third to be approved in the United States for APAS, a novel technology that has successfully been shown to assess microbiology samples for the presence of disease-causing bacteria, with significant implications for laboratory efficiency. The core APAS technology is currently the subject of a 510(k) *de novo* submission to the US Food and Drug Administration (FDA), seeking classification of APAS as a Class II medical device and 510(k) clearance for marketing in the United States.

The latest Notice of Allowance relates to patent application no. 14/002,703, which covers the image capture and lighting apparatus of the APAS technology. It follows a Notice of Allowance issued last October for the key systems and analytical software of APAS, and a patent issued in March 2015 for a novel method used to 'colour calibrate' images captured by APAS. The three patents and notices all provide for 20 years of patent protection, and are part of a portfolio of four inventions related to APAS, for which LBT initiated intellectual property protection in 2011.

The latest patent notice comes just days before the 9 April unveiling of the first APAS instrument, the APAS® Independence, at the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam.

The APAS® Independence is an automated culture plate reader and sorter that integrates APAS with high-speed robotic plate-handling equipment in a world-first plate-handling solution. The instrument will be unveiled by Clever Culture Systems AG, the joint venture established by LBT and its 50-50 development partner, Hettich AG Switzerland.

The APAS Independence will be accompanied by a poster on the *Validation of APAS as an effective device for the screening of urine specimens*. The poster is being presented by Prof Stephen Young, Professor of Pathology, Director of Research and Clinical Trials, Scientific Director Infectious Diseases at TriCore Reference Laboratories, Albuquerque USA, where a large-scale clinical trial for APAS was successfully conducted last year.

– ENDS –

About LBT Innovations

LBT Innovations is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company has two breakthrough products in microbiology automation: MicroStreak®, which provides automation of culture plate streaking, and APAS®, a breakthrough in automated culture plate reading, interpretation and reporting. Based on LBT's innovative intelligent image interpretative platform, APAS specifically addresses the automated imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a joint venture with Hettich AG Switzerland to drive the commercialisation of APAS products. LBT also has a third product in development, Woundvue™, a proposed automation solution to assist in the management of chronic wounds. For more information, see www.lbtinnovations.com

CONTACTS

Clever Culture Systems AG	LBT Innovations Ltd	Media Relations
Peter Bradley General Manager Tel: +61 (0)8 8227 1555 E: pmb@cleverculturesystems.com	Lusia Guthrie CEO, LBT Innovations Tel: +61 (0)8 8227 1555 E: info@lbtinnovations.com	Rudi Michelson Monsoon Communications Tel: +61 (0)3 9620 3333 E: rudim@monsoon.com.au